CN Patent

CN114901821A — Sept9抑制剂用于治疗乙型肝炎病毒感染的用途

Assigned to F Hoffmann La Roche AG · Expires 2022-08-12 · 4y expired

What this patent protects

本发明涉及一种SEPT9抑制剂，其用于治疗HBV感染，特别是慢性HBV感染。本发明特别地涉及SEPT9抑制剂用于使cccDNA，诸如HBVcccDNA去稳定的用途。本发明还涉及与SEPT9互补并且能够降低SEPT9mRNA的水平的核酸分子。本发明还包括一种药物组合物及其在HBV感染的治疗中的用途。

USPTO Abstract

本发明涉及一种SEPT9抑制剂，其用于治疗HBV感染，特别是慢性HBV感染。本发明特别地涉及SEPT9抑制剂用于使cccDNA，诸如HBVcccDNA去稳定的用途。本发明还涉及与SEPT9互补并且能够降低SEPT9mRNA的水平的核酸分子。本发明还包括一种药物组合物及其在HBV感染的治疗中的用途。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN114901821A
Jurisdiction: CN
Classification: —
Expires: 2022-08-12
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.